These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Tada H; Kawashiri MA; Nohara A; Inazu A; Mabuchi H; Yamagishi M Eur Heart J; 2017 May; 38(20):1573-1579. PubMed ID: 28159968 [TBL] [Abstract][Full Text] [Related]
29. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia. Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860 [TBL] [Abstract][Full Text] [Related]
30. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
31. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
32. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis. Di Taranto MD; D'Agostino MN; Fortunato G Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):979-87. PubMed ID: 26165249 [TBL] [Abstract][Full Text] [Related]
33. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824 [TBL] [Abstract][Full Text] [Related]
34. Homozygous familial hypercholesterolaemia: update on management. France M Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828 [TBL] [Abstract][Full Text] [Related]
36. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [TBL] [Abstract][Full Text] [Related]
37. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis. Kwon M; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo J; Hur SH; Jeong JO; Jang Y; Lee SH; Lee JH Atherosclerosis; 2015 Sep; 242(1):8-12. PubMed ID: 26160041 [TBL] [Abstract][Full Text] [Related]
39. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Ogura M; Hori M; Harada-Shiba M Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):181-8. PubMed ID: 26543100 [TBL] [Abstract][Full Text] [Related]
40. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Goldberg AC; Hopkins PN; Toth PP; Ballantyne CM; Rader DJ; Robinson JG; Daniels SR; Gidding SS; de Ferranti SD; Ito MK; McGowan MP; Moriarty PM; Cromwell WC; Ross JL; Ziajka PE J Clin Lipidol; 2011; 5(3):133-140. PubMed ID: 21600517 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]